Altimmune is proud to be working on solutions to address the global SARS-CoV-2 pandemic. Using our proprietary intranasal vaccine technology, we have developed a novel COVID-19 vaccine candidate (AdCOVID™) with unique attributes designed to prevent infection and transmission of the virus.
We are also advancing development of a novel therapeutic candidate (T-COVID™) designed to protect patients with early COVID-19 infection from developing more severe symptoms and the need for hospitalization.
Read on to learn more about how AdCOVID™ and T-COVID™ can help in the fight against the SARS-CoV-2 coronavirus.